StreetInsider.com News Articles

Form SCHEDULE 13G Adicet Bio, Inc. Filed by: Zedek Daniel Clayton

Fri, 23 Oct 2026 17:49:00 -0400

si-local-file:///var/storage/secattach/20261023/27228735.html

Adicet Bio to Participate in Upcoming Investor Conferences

Thu, 22 Oct 2026 16:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that company management will participate in two upcoming investor conferences in November.

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA

Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET

Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK

Members of

Adicet Bio to Participate in Upcoming Investor Conferences

Thu, 22 Oct 2026 16:00:00 -0400

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA

Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET

Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK

Members of

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 19:12:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on September 30, 2026.

One individual was hired by Adicet in September 2026 and granted new hire non-qualified stock options to purchase 725 shares of Adicet’s common stock with an exercise price of $7.14 per share, the closing price of Adicet’s common stock as reported by Nasdaq on September 30, 2026. One-fourth of the shares

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 19:12:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on September 30, 2026.

Adicet Bio Inc. (ACET) PT Raised to $34 at H.C. Wainwright

Tue, 29 Sep 2026 06:48:41 -0400

(Updated - September 29, 2026 6:48 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $34.00 (from $27.00) while maintaining a Buy rating.

The analyst commented: "Earlier today, Adicet announced updated results for prula-cel in 24 patients, including 16 with lupus nephritis (LN) and eight with extra-renal systemic lupus erythematosus (SLE). At baseline, patients had a mean SLEDAI-2K score of 13 and a mean urine protein-to-creatinine ratio (uPCR) of 2.8, while 71% had received prior therapy. At 12 months, 50% of evaluable LN patients (5/10) achieved a complete renal response (CRR), and 54%

Adicet Bio Inc. (ACET) PT Raised to $34 at H.C. Wainwright

Tue, 29 Sep 2026 06:48:41 -0400

(Updated - September 29, 2026 6:48 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $34.00 (from $27.00) while maintaining a Buy rating.

Adicet Bio Inc. (ACET) PT Raised to $28 at Wedbush

Mon, 28 Sep 2026 09:57:46 -0400

Wedbush analyst Robert Driscoll raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $28.00 (from $25.00) while maintaining a Outperform rating.

The analyst comments "ACET reported maturing data from SLE/LN patients treated with allogeneic gamma-delta T-cell therapy prula-cel, demonstrating impressive efficacy (50% CRR, 54% DORIS remission) and safety, with all patients discontinuing background immunosuppressants. Across 22 heavily pretreated efficacy evaluable patients (16 LN, 6 extra-renal SLE; mean baseline SLEDAI-2K of 13 and mean UPCR of 2.8, with 71% of patients having received four or more prior therapies) with follow-up ranging from 6 to 21 months, 50% of evaluable LN

Adicet Bio Inc. (ACET) PT Raised to $28 at Wedbush

Mon, 28 Sep 2026 09:57:46 -0400

Wedbush analyst Robert Driscoll raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $28.00 (from $25.00) while maintaining a Outperform rating.

Form 8-K Adicet Bio, Inc. For: Sep 28

Mon, 28 Sep 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260928/27110472.html

Adicet Bio reports Phase 1 lupus trial data for prula-cel

Mon, 28 Sep 2026 06:46:01 -0400

Adicet Bio, Inc. (Nasdaq: ACET) released Phase 1 clinical data for prulacabtagene leucel (prula-cel), an investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), according to a company statement.

The data, cut off as of August 28, 2026, covered 22 efficacy-evaluable patients — 16 with LN and 6 with extra-renal SLE — with follow-up ranging from 6 to 21 months. All patients had received at least three prior therapies, with 71% having received four or more.

At 12 months, 54% of evaluable patients achieved DORIS remission, and 50% of evaluable LN

Adicet Bio reports Phase 1 lupus trial data for prula-cel

Mon, 28 Sep 2026 06:46:01 -0400

At 12 months, 54% of evaluable patients achieved DORIS remission, and 50% of evaluable LN

Adicet Bio reports Phase 1 lupus trial data for prula-cel

Mon, 28 Sep 2026 06:46:01 -0400

At 12 months, 54% of evaluable patients achieved DORIS remission, and 50% of evaluable LN

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Mon, 28 Sep 2026 06:45:00 -0400

- Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS -

-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR-

-All patients discontinued immunosuppressants –

- All but one patient tapered background steroids to ≤5 mg prednisone equivalent per day-

-Rapid reductions in SLEDAI-2K and PGA scores, consistent with autologous alpha beta CAR-T cell therapies-

-Plan to initiate pivotal lupus nephritis trial start-up activities in 4Q/2026; high DORIS remission rate may support expansion of pivotal study to include lupus without nephritis based on

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Mon, 28 Sep 2026 06:45:00 -0400

- Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS -
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR-
-All patients discontinued immunosuppressants –
- All but one patient tapered background steroids to ≤5 mg prednisone equivalent per day-
-Rapid reductions in SLEDAI-2K and PGA scores, consistent with autologous alpha beta CAR-T cell therapies-
-Plan to initiate pivotal lupus nephritis trial start-up activities in 4Q/2026; high DORIS remission rate may support expansion of pivotal study to include lupus without nephritis based on

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Fri, 25 Sep 2026 16:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis on Monday, September 28, 2026. Following the announcement, the company will host a webcast presentation at 8:00am ET to discuss the results.
Webcast/Conference Call Information
The live webcast of the presentation can

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Fri, 25 Sep 2026 16:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis on Monday, September 28, 2026. Following the announcement, the company will host a webcast presentation at 8:00am ET to discuss the results.
Webcast/Conference Call Information
The live webcast of the presentation can

H.C. Wainwright Reiterates Buy Rating on Adicet Bio Inc. (ACET)

Mon, 21 Sep 2026 07:33:22 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $27.00 price target on Adicet Bio Inc. (NASDAQ: ACET).
The analyst commented: "We draw investors’ attention to Adicet’s upcoming clinical data update for prulacabtagene leucel (prula-cel; formerly ADI-001), its CD20-targeted allogeneic gamma delta CAR-T cell therapy being evaluated in lupus nephritis (LN) and systemic lupus erythematosus (SLE), which is expected by month-end. The planned analysis will include 22 patients with SLE, with or without LN, who have at least six months of follow-up, including 13 patients with at least 12 months of follow-up. For context, the only similarly sized cell therapy

FDA clears Adicet Bio IND application for prostate cancer therapy

Thu, 27 Aug 2026 16:00:41 -0400

Adicet Bio, Inc. (Nasdaq: ACET) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ADI-212, a cell therapy candidate targeting metastatic castration-resistant prostate cancer (mCRPC).
According to the press release, the company plans to begin Phase 1 enrollment in patients with mCRPC in the fourth quarter of 2026.
ADI-212 is described as a gene-edited cell therapy targeting prostate-specific membrane antigen (PSMA). It incorporates membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated disruption of subunit 12 of the mediator complex, designed to act within the tumor microenvironment.
Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio, said the therapy is

FDA clears Adicet Bio IND application for prostate cancer therapy

Thu, 27 Aug 2026 16:00:41 -0400

Adicet Bio, Inc. (Nasdaq: ACET) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ADI-212, a cell therapy candidate targeting metastatic castration-resistant prostate cancer (mCRPC).
According to the press release, the company plans to begin Phase 1 enrollment in patients with mCRPC in the fourth quarter of 2026.
ADI-212 is described as a gene-edited cell therapy targeting prostate-specific membrane antigen (PSMA). It incorporates membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated disruption of subunit 12 of the mediator complex, designed to act within the tumor microenvironment.
Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio, said the therapy is

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Thu, 27 Aug 2026 16:00:00 -0400

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Thu, 27 Aug 2026 16:00:00 -0400

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Thu, 27 Aug 2026 16:00:00 -0400

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Thu, 27 Aug 2026 16:00:00 -0400

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Thu, 27 Aug 2026 16:00:00 -0400

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with